Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.

Abstract: The purpose of the present invention is to provide a methyl methacrylate-containing composition with high quality stability during storage. This can be solved with a methyl methacrylate-containing composition, a pyrazine compound represented by Formula (1) (component A1), and a polymerization inhibitor (Component B1), in which the concentration of methyl methacrylate is from 99 to 99.99% by mass.

Abstract: An API adapter generation device include a conversion rule calculation unit (16) configured to acquire a data model of an orchestrator (210) and an API specification to be managed and perform schema matching on the basis of a data schema of the orchestrator and a data schema of the API specification to calculate a model conversion rule, a call logic unit generation unit (19) configured to rewrite a source code of an API call logic unit 232 describing an API adapter execution logic on the basis of the model conversion rule, and an API adapter generation unit (21) configured to generate an API adapter to be managed on the basis of the API call logic unit in which the source code is rewritten.

Abstract: A method and system for robot motion control using a model predictive control (MPC) technique including torque rate control and suppression of end tooling oscillation. An MPC module includes a robot dynamics model which inherently reflects response nonlinearities associated with changes in robot configuration, and an optimization solver having an objective function with a torque rate term and inequality constraints defining bounds on both torque and torque rate. The torque rate control in the MPC module provides an effective means of controlling jerk in robot joints, while accurately modeling robot dynamics as the robot changes configuration during a motion program. End tooling oscillation dynamics may also be included in the MPC objective function and constraints in order to automatically control end tooling vibration in the calculations of the MPC module.

Abstract: A liquid-repellent structure includes a surface to which liquid repellency is to be imparted; a foundation layer having a surface and disposed to face the surface to which liquid repellency is to be imparted; and a liquid-repellent layer disposed to face the surface of the foundation layer, wherein the foundation layer contains an acid-modified polyolefin, the liquid-repellent layer contains a fluorine-containing resin and particles, and the fluorine-containing resin contains a hydrophilic structural unit having at least one of an amino group and an amide group. A packaging material has the liquid-repellent structure disposed to face a product. The packaging material can also be applied to a product that is a selected one of hand soap, body soap, shampoo, rinse, creams, and cosmetics and that contains a surfactant.

Abstract: A method for tuning the force control parameters for a general robotic assembly operation. The method uses numerical optimization to evaluate different combinations of the parameters for a robot force controller in a simulation environment that is built based on a real-world robotic setup. This method performs autonomous tuning for assembly tasks based on closed loop force control simulation, where random samples from a distribution of force control parameter values are evaluated, and the optimization routine iteratively redefines the parameter distribution to find optimal values of the parameters. Each simulated assembly is evaluated using multiple simulations including random part positioning uncertainties. The performance of each simulated assembly is evaluated by the average of the simulation results, thus ensuring that the selected control parameters will perform well in most possible conditions.

Abstract: A display apparatus includes display elements formed on a substrate and arrayed in a two-dimensional matrix, the display elements each having a light emitting unit formed by stacking a lower electrode, an organic layer, and an upper electrode, wherein the lower electrode and the organic layer are provided for each light emitting unit, the substrate includes a groove formed in a part of the substrate positioned between adjacent light emitting units, the groove having a bottom surface and both side surfaces forming a gentle inclination angle with respect to the bottom surface, and a protective film is formed in common on entire surface including an upper surface of the light emitting unit and an upper surface of the groove of the substrate.

Abstract: The present invention has been made in view of the foregoing, and an object thereof is to provide an information processing device capable of appropriately determining a necessity of the ultrasonography even when a high-density mammary gland area exists in a narrow area. The present invention provides an information processing device comprising: a mammary gland area extractor configured to extract a mammary gland area in a mammography image; a mammary gland pixel detector configured to detect a mammary gland pixel in the mammary gland area; and a mammary gland density calculator configured to calculate a mammary gland density based on a ratio of the mammary gland pixels to the mammary gland area, wherein the mammary gland area is a narrower area than an entire breast in the mammography image.

Abstract: There is provided an imaging device including an upper electrode; a lower electrode; a photoelectric conversion layer disposed between the upper electrode and the lower electrode; and a first organic semiconductor material including an indolocarbazole derivative and disposed between the upper electrode and the lower electrode. Further, there is provided an electronic apparatus including an imaging device that includes an upper electrode; a lower electrode; a photoelectric conversion layer disposed between the upper electrode and the lower electrode; and a first organic semiconductor material including an indolocarbazole derivative and disposed between the upper electrode and the lower electrode.

Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.

Abstract: An organic EL device is constructed with a structure that can prevent deterioration in characteristics. An organic EL device is provided that includes at least two or more subpixels each including an organic compound layer including at least a light-emitting layer that emits light of a different color from the other light-emitting layer(s), the organic compound layer being interposed between a first electrode and a second electrode in a stacking manner, the subpixels being disposed separately from one another on a plane perpendicular to a direction of the stacking. Lateral surfaces of the organic compound layers are covered with films differing from subpixel to subpixel. This structure can prevent the organic EL device from deterioration in characteristics.

Abstract: An operating device for a human-powered vehicle comprises a base, a piston, an operating member, an intermediate member, and a mounting structure. The base includes a hole. The piston is movably provided in the hole. The operating member is pivotally coupled to the base about a first pivot axis. The intermediate member is pivotally coupled to the base about a second pivot axis to transmit a pivotal movement of the operating member to the piston. The mounting structure is configured to couple the base and a handlebar of the human-powered vehicle. The mounting structure defines a mounting axis extending along the handlebar in a mounting state where the mounting structure couples the base and the handlebar. The first pivot axis is closer to the mounting axis than the second pivot axis in a perpendicular direction perpendicular to the mounting axis as viewed along the first pivot axis.

Abstract: An organic EL device is constructed with a structure that can prevent deterioration in characteristics. An organic EL device is provided that includes at least two or more subpixels each including an organic compound layer including at least a light-emitting layer that emits light of a different color from the other light-emitting layer(s), the organic compound layer being interposed between a first electrode and a second electrode in a stacking manner, the subpixels being disposed separately from one another on a plane perpendicular to a direction of the stacking. Lateral surfaces of the organic compound layers are covered with films differing from subpixel to subpixel. This structure can prevent the organic EL device from deterioration in characteristics.

Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

Abstract: An information processing device including: a data acquiring unit; and a data calculator. The data acquiring unit is configured to acquire medical image data and additional data, the additional data includes at least one of monitor-related data and/or environmental data, the monitor-related data is data for defining a visibility of an image displayed on a display unit of a monitor, the environmental data is data indicating an ambient environment of the monitor, and the data calculator is configured to calculate overlooking suppression data based on the medical image data and the additional data, the overlooking suppression data is data that suppresses overlooking of a lesion in the medical image data.

Abstract: [Problem] Provided are a photoelectric conversion device and an imaging apparatus capable of improving quantum efficiency and a response speed. [Solving means] A first photoelectric conversion device according to one embodiment of the present disclosure includes a first electrode, a second electrode opposed to the first electrode, and a photoelectric conversion layer. The photoelectric conversion layer is provided between the first electrode and the second electrode and includes at least one type of one organic semiconductor material having crystallinity. Variation in a ratio between horizontally-oriented crystal and vertically-oriented crystal in the photoelectric conversion layer is three times or less between a case where film formation of the one organic semiconductor material is performed at a first temperature and a case where the film formation of the one organic semiconductor material is performed at a second temperature. The second temperature is higher than the first temperature.

Abstract: In a display device, sub-pixels each having a structure in which a first electrode and a second electrode are laminated with an organic compound layer having a light emitting layer interposed therebetween are provided in such an arrangement pattern that the sub-pixels are separated from each other two-dimensionally, and the second electrode is patterned so as to straddle the sub-pixels and be connected between the sub-pixels, and includes a plurality of branching portions connected to each other, and the branching portions are two-dimensionally arranged.

Abstract: A display device includes an anode electrode, an organic light emitting layer, and a first cathode electrode. Provided are a plurality of light emitting elements in which the anode electrode, the organic light emitting layer, and the first cathode are separated for each sub-pixel, a protective layer covering the plurality of light emitting elements, and a second cathode electrode provided on the protective layer. The second cathode electrode is connected to each separated first cathode electrode.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.